Tuesday, May 2, 2017 6:00 – 8:30 PM
Phenotypic Screening Applications and Technologies
Steven Rust, Ph.D., Senior Manager, R&D, MedImmune, United Kingdom
Antibody drug discovery has predominantly relied upon target-specific approaches for clinical success. However, as the search for well-validated, antibody-tractable targets becomes more challenging and target space becomes increasingly competitive alternative approaches, such as “target-agnostic” phenotypic screening, are gaining favor. This short course will highlight successful antibody phenotypic screens that have led to clinical drug candidates as well as the requirements for performing an effective antibody phenotypic screen, including antibody enrichment and target identification strategies. Finally, it will also discuss the potential impact that cutting-edge technologies; such as single-cell screening, microfluidics, NGS and high-content screening, will have on the success of antibody phenotypic screening.
- Historical perspective of successful antibody phenotypic screens, which have led to clinical
- drug candidates.
- Planning for a successful antibody phenotypic screen.
- Improvements in established technologies that support antibody phenotypic screening; such
- as target identification strategies.
- Advances in screening technologies, such as single-cell screening, microfluidics, NGS and high content screening, and their potential impact on phenotypic screening.
- Impact of phenotypic drug discovery on antibody drug pipelines.
Speaker Biography:
Steven Rust, Ph.D., Senior Manager, R&D, MedImmune, United Kingdom
Steve Rust currently leads the antibody phenotypic screening group at MedImmune. This group is responsible for performing target-agnostic antibody screens, and evaluating new technologies, across multiple therapy areas. Whilst at Cambridge Antibody Technology, he gained experience working on a number a therapeutic antibody programs. Prior to joining Cambridge Antibody Technology, he completed his undergraduate studies in Cellular and Molecular Biology and spent a number of years researching model plant and fungal systems to develop methods for novel target identification and validation.